PRPO Precipio
- 6.0250
- -0.1500-2.43%
Precipio News
Precipio Inc Schedules Year-End Shareholder Update Call
Precipio Announces Year End 2023 Shareholder Update Call
NEW HAVEN, Conn., March 25, 2024 (GLOBE NEWSWIRE) -- Specialty cancer diagnostics company Precipio, Inc. (NASDAQ:PRPO), will be hosting its year end 2023 corporate update call on April 1st, 2024 at 5:00 PM ET. The call
Precipio to Report $15.2M for FY-2023 (Unaudited) Revenues, an Increase of 60% YoY
NEW HAVEN, Conn., Feb. 13, 2024 (GLOBE NEWSWIRE) -- Specialty cancer diagnostics company Precipio, Inc. (NASDAQ:PRPO), announces that for the full year of 2023, its unaudited revenues have grown from $9.4M in 2022 to
Express News | Precipio Shares Halted On Circuit Breaker To The Upside, Stock Now Up 6.46%
Precipio and Cardinal Health Sign Distribution Agreement for Its HemeScreen Portfolio of Molecular Assays for Cancer
NEW HAVEN, Conn., Feb. 06, 2024 (GLOBE NEWSWIRE) -- Specialty cancer diagnostics company Precipio, Inc. (NASDAQ:PRPO) announces it has entered into a distribution agreement with Cardinal Health for its HemeScreen
Press Release: Precipio's Q4-2023 Cash Burn From Operations (Unaudited) Drops Below $100K for the Full Quarter
Precipio's Q4-2023 Cash Burn From Operations (unaudited) drops below $100K for the full quarter Results clearly demonstrate the business's ability to reach breakeven in the near future NEW HAVEN, Co
Precipio Shares Climb on Deal to Sell Products in Japan
By Sabela Ojea Shares of Precipio on Wednesday climbed after the cancer-diagnostics company said it would distribute its products in Japan. At 10:59 a.m. ET, shares were up 11%, at $5.85. The stock
Press Release: Precipio Announces Christina Valauri Joins the Board of Directors
Precipio Announces Christina Valauri joins the Board of Directors Douglas Fisher, MD will step down as Director, and remain as a board observer NEW HAVEN, Conn., Jan. 02, 2024 (GLOBE NEWSWIRE) -- Sp
Precipio Management Shares Thoughts on 2023, and Looks Ahead To 2024
NEW HAVEN, Conn., Dec. 14, 2023 (GLOBE NEWSWIRE) -- Management of specialty cancer diagnostics company Precipio, Inc. (NASDAQ:PRPO) shares thoughts and reflections looking back at 2023, and forward to 2024. At the
Earnings Call: Precipio's Q3 2023 Results Show Strong Growth and Approach to Breakeven
Notable Earnings After Monday's Close
Precipio Announces Q3-2023 Shareholder Update Call
NEW HAVEN, Conn., Nov. 16, 2023 (GLOBE NEWSWIRE) -- Specialty cancer diagnostics company Precipio, Inc. (NASDAQ:PRPO), will be hosting its Q3-2023 corporate update call on November 20th, 2023 at 5:00 PM ET. The call
Precipio Set to Reach Profitability in 2024 With Strong Growth Forecast
Market Might Still Lack Some Conviction On Precipio, Inc. (NASDAQ:PRPO) Even After 27% Share Price Boost
Precipio, Inc. (NASDAQ:PRPO) shareholders would be excited to see that the share price has had a great month, posting a 27% gain and recovering from prior weakness. Unfortunately, the gains of the
Precipio Sees Q3 Revenue $4.5M Vs $4M Est.
Specialty cancer diagnostics company Precipio, Inc. (NASDAQ:PRPO), announces that Q3-2023 (unaudited) revenues have increased 28% to $4.5M from $3.5M in Q2-2023, and have more than doubled from $2.2M
Press Release: Precipio to Report $4.5M Q3-2023 Revenues, Double From Q3-2022
Precipio to Report $4.5M Q3-2023 Revenues, Double From Q3-2022 28% Revenue Increase Is Major Step Toward Company Breakeven NEW HAVEN, Conn., Oct. 18, 2023 (GLOBE NEWSWIRE) -- Specialty cancer diagno
Precipio Inc Has Regained Compliance With Nasdaq Bid Price Rule
Precipio Inc Has Regained Compliance With Nasdaq Bid Price Rule
Precipio's Q3 Cash Burn From Operations (Unaudited) Declines 59% YoY, From $2.5M in Q3-2022 to Approximately $1M in Q3-2023
Precipio Continues to Sign New HemeScreen Customers
NEW HAVEN, Conn., Sept. 28, 2023 (GLOBE NEWSWIRE) -- Specialty cancer diagnostics company Precipio, Inc. (NASDAQ:PRPO) announced that new customer orders are expected to bring total Q4 HemeScreen revenues to an
Precipio: Due to the Increased Pathology Rev, and the Recent Operational Efficiencies, the Co Has Reduced the Rev Required From the Products Division to Reach Breakeven From $8M to $6M Annually, or $1.5M Per Qtr, 25% Below Previous Estimates >PRPO
Precipio: Due to the Increased Pathology Rev, and the Recent Operational Efficiencies, the Co Has Reduced the Rev Required From the Products Division to Reach Breakeven From $8M to $6M Annually, or $1
Analysis
Price Target
No Data
